Find the Perfect Plan for Your Investment Journey
C
Latest price
52 Week Range
HK$16.34 - HK$42.20
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | HK$10.78B |
EV | HK$9.52B |
Shares Outstanding | 247.04M |
Beta | 1.35 |
Analyst Rating | BUY |
Analyst Target Price | HK$36.02 |
P/E 2025E | - |
P/Revenue 2025E | 8.80x |
Revenue | -42.30% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | 41.60% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 77.70% |
Net Profit Margin 2025E | -0.01% |
ROE 2025E | 0.02% |
ROCE 2024 | -7.33% |
DPS 2025E | HK$0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
C
CanSino Biologics Inc.
6185
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yu, Xuefeng
Employees
1,494
Website
www.cansinotech.comIPO Date
2019-03-28
Headquarters
401-420, Biomedical Park, 4th Floor, 185 South Avenue, TEDA West District, Tianjin 300457, China
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved